Amgen Q1 product sales up 11.5%; adjusted earnings up 11%

Amgen (NASDAQ:AMGN) Q1 results:

Revenues: $6,161M (+10.9%); product sales:$5,894M (+11.5%).

Top sellers: Enbrel: $1,153M (+0.2%); Neulasta: $609M (-40.4%); Prolia: $654M (+10.5%); Xgeva: $481M (+2.1%); Repatha: $229M (+62.4%); Aimovig: $71M (+20.3%); Evenity: $100M (+488.2%).

Net income: $1,825M (-8.6%); non-GAAP net income: $2,476M (+11.0%); EPS:; non-GAAP EPS: $4.17 (+17.1%).

Cash flow ops: $2.1B (+16.7%).

2020 guidance: Revenues: $25.0B – 25.6B (unch); EPS: $10.65 – 11.45 from $10.85 – 11.65; non-GAAP EPS: $14.85 – 15.60 (unch).

Amgen EPS beats by $0.42, beats on revenue

https://seekingalpha.com/news/3567164-amgen-q1-product-sales-up-11_5-adjusted-earnings-up-11